Skip to Main Content

Author Details

Nadia Traficante
Peter MacCallum Cancer Centre
2002
32
20
PMIDPaper TitleJournal TitlePublished Year
36366810Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan.J Gynecol Oncol2023
36366810Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan.J Gynecol Oncol2023
38028140The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.Ther Adv Med Oncol2023
37858159UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer.J Exp Clin Cancer Res2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
36948887p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2023
36790339Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma.Cancer Epidemiol Biomarkers Prev2023
38028140The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.Ther Adv Med Oncol2023
37858159UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer.J Exp Clin Cancer Res2023
36948887p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2023
36790339Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma.Cancer Epidemiol Biomarkers Prev2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
35263119TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.J Clin Oncol2022
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
35263119TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.J Clin Oncol2022
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
32546565Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high-grade serous ovarian cancer.J Med Genet2021
34031395Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.Nat Commun2021
34321239Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.Cancer Res2021
32546565Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high-grade serous ovarian cancer.J Med Genet2021
34321239Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.Cancer Res2021
34031395Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.Nat Commun2021
32473302Prognostic gene expression signature for high-grade serous ovarian cancer.Ann Oncol2020
32107557Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D.J Natl Cancer Inst2020
32473302Prognostic gene expression signature for high-grade serous ovarian cancer.Ann Oncol2020
32555365Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.Br J Cancer2020
32554541Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).Clin Cancer Res2020
32107557Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D.J Natl Cancer Inst2020
32555365Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.Br J Cancer2020
32554541Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).Clin Cancer Res2020
30967419Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype.Clin Cancer Res2019
30967419Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype.Clin Cancer Res2019
29531130Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.Cancer Epidemiol Biomarkers Prev2018
35135122<i>BRAF</i> Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition.JCO Precis Oncol2018
30266954Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.Nat Commun2018
29531130Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.Cancer Epidemiol Biomarkers Prev2018
29502561MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.Mayo Clin Proc2018
29807697Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.Gynecol Oncol2018
35135122<i>BRAF</i> Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition.JCO Precis Oncol2018
29807697Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.Gynecol Oncol2018
30266954Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.Nat Commun2018
29502561MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.Mayo Clin Proc2018
27798111The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer.Hum Mol Genet2016
26574572CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer.Endocr Relat Cancer2016
27798111The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer.Hum Mol Genet2016
26574572CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer.Endocr Relat Cancer2016
26017449Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
25852062Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.Mol Cancer Ther2015
26017449Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
26503049Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
  • 1 - 50 of 64

Recommended Authors

Pier Selenica
Memorial Sloan Kettering Cancer Center
Career Start Year 2017
Number of shared co-authors 8
Yukie Bean
Oregon Health & Science University
Career Start Year 2013
Number of shared co-authors 81
Guanglong Jiang
Indiana University School of Medicine
Career Start Year 2011
Number of shared co-authors 0
Yuexin Liu
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 6
Ghassan Allo
Henry Ford Hospital
Career Start Year 2011
Number of shared co-authors 9
Cristina Ivan
The University of Texas MD Anderson Cancer Center
Career Start Year 2010
Number of shared co-authors 5
Darragh G McArt
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 1
Salvatore Piscuoglio
University of Basel
Career Start Year 2008
Number of shared co-authors 3
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 1
Markus Riester
Novartis Institutes for BioMedical Research
Career Start Year 2005
Number of shared co-authors 3
Andrew H Beck
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 2004
Number of shared co-authors 22
Leah M Prentice
British Columbia Women's Hospital and Health Centre
Career Start Year 2004
Number of shared co-authors 37
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 5
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 2
Leslie Cope
Johns Hopkins University School of Medicine
Career Start Year 2003
Number of shared co-authors 4
Karin Jirstr??m
Lund University
Career Start Year 2003
Number of shared co-authors 4
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 8
Siddhartha Deb
Olivia Newton-John Cancer Research Institute
Career Start Year 2002
Number of shared co-authors 3
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 0
Habib Hamidi
Genentech Inc.
Career Start Year 2002
Number of shared co-authors 15
Britta Weigelt
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 29
Blaise A Clarke
University of Toronto.
Career Start Year 2001
Number of shared co-authors 47
Steve E Kalloger
University of British Columbia
Career Start Year 2000
Number of shared co-authors 29
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 28
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 4
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 4
Paulette Mhawech-Fauceglia
University of Southern California
Career Start Year 1995
Number of shared co-authors 11
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 46
Anil K Sood
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 34
Patricia A Shaw
Princess Margaret Cancer Centre, University Avenue
Career Start Year 1990
Number of shared co-authors 49

Collaborators

David D L Bowtell
Peter MacCallum Cancer Centre
Co-authored papers 31
Sian Fereday
Peter MacCallum Cancer Centre
Co-authored papers 22
Anna DeFazio
Westmead Hospital
Co-authored papers 20
Catherine J Kennedy
The Westmead Institute for Medical Research, University of Sydney
Co-authored papers 12
Susan J Ramus
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
Co-authored papers 11
Paul Harnett
Westmead Clinical School, University of Sydney
Co-authored papers 11
Ellen L Goode
Mayo Clinic College of Medicine
Co-authored papers 10
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 10
Stacey J Winham
Mayo Clinic
Co-authored papers 10
Joy Hendley
Peter MacCallum Cancer Centre
Co-authored papers 9
Usha Menon
College of Nursing, University of South Florida
Co-authored papers 9
Jacek Gronwald
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 9
Michael S Anglesio
University of British Columbia
Co-authored papers 8
Joshy George
Peter MacCallum Cancer Centre
Co-authored papers 8
James D Brenton
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 8
Kathryn Alsop
Peter MacCallum Cancer Centre
Co-authored papers 8
Martin K??bel
University of Calgary
Co-authored papers 8
Yoke-Eng Chiew
Westmead Hospital
Co-authored papers 7
Stefan Kommoss
Eberhard Karls University Tubingen
Co-authored papers 7
Georgia Chenevix-Trench
QIMR Berghofer Medical Research Institute
Co-authored papers 7
Simon A Gayther
Cedars-Sinai Medical Center
Co-authored papers 7
David G Huntsman
University of British Columbia
Co-authored papers 7
Jenny Lester
David Geffen School of Medicine, University of California at Los Angeles
Co-authored papers 7
Jennifer Alsop
University of Cambridge
Co-authored papers 7
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 7
Javier Ben??tez
Instituto de Salud Carlos III
Co-authored papers 6
Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Co-authored papers 6
Mercedes Jimenez-Linan
University of Cambridge
Co-authored papers 6
Aline Talhouk
The University of British Columbia
Co-authored papers 6
Marc T Goodman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 6
Release 1.2